Background: Although cognitive deficits in bipolar disorder (BD) have been repeatedly observed, our understanding of these impairments at a mechanistic level remains limited. Few studies that investigated cognitive impairments in bipolar illness have examined the association with brain biochemistry. This pilot study utilized proton magnetic resonance spectroscopy (H-MRS) to evaluate the relationship between neurocognitive performance and brain metabolites in youth with BD.
Methods: Thirty participants, twenty depressed BD participants and ten healthy comparison participants, ages 13-21, completed mood and executive function measures. H-MRS data were also acquired from the anterior cingulate cortex (ACC) using two-dimensional (2D) J-resolved H-MRS sequence. Proton metabolites including N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) were quantified for both groups.
Results: Participants with BD performed significantly lower on executive functioning measures than comparison participants. There were significant positive correlations between Wisconsin Card Sorting Test (WCST) performance and NAA (p < .001) and GABA (p < .01) in the ACC in bipolar youth, such that as WCST performance increased, both NAA and GABA levels increased.
Limitations: Small sample size and lack of control for medications.
Conclusions: These findings build on previous observations of biochemical alterations associated with BD and indicate that executive functioning deficits in bipolar youth are correlated with NAA and GABA. These results suggest that cognitive deficits occur early in the course of illness and may reflect risk factors associated with altered neurochemistry. Further investigation of the relationship between brain metabolites and cognition in BD may lead to important information for developing novel, targeted interventions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jad.2017.07.052 | DOI Listing |
Aust N Z J Psychiatry
January 2025
Centre for Mental Health, Swinburne University of Technology, Melbourne, VIC, Australia.
Objective: Neurocognitive underpinnings are implicated in the aetiology and maintenance of body dysmorphic disorder (BDD); however, inconsistent findings across a range of neurocognitive domains suggest that a comprehensive synthesis of the literature using a hierarchical framework of neurocognition is needed.
Methods: A final search across OVID Medline, PsycNET, Scopus and Web of Science databases was conducted on 20 June 2024 to identify research that examined performance on behavioural tasks of objective neurocognition in BDD. Risk of bias was assessed using the Newcastle-Ottawa Scale.
As of 2023, 69% of adults and 81% of teens in the U.S. use social media.
View Article and Find Full Text PDFApolipoprotein E4 (APOE4) is the strongest genetic risk factor for sporadic Alzheimer's disease (AD). Individuals with one copy of APOE4 exhibit greater amyloid-beta (Aβ) deposition compared to noncarriers, an effect that is even more pronounced in APOE4 homozygotes. Interestingly, APOE4 carriers not only show more AD pathology but also experience more rapid cognitive decline, particularly in episodic memory.
View Article and Find Full Text PDFPLoS One
January 2025
MSH Medical School Hamburg, University of Applied Sciences and Medical University, Hamburg, Germany, Europe.
Bright daylight has various positive influences, such as the long-term synchronization of circadian rhythms and an associated alertness that creates optimal conditions for attentional performance. However, the short-term effects of light on attention have not yet been sufficiently researched. Studies of these short-term effects on selective attention also showed partly contradictory effects.
View Article and Find Full Text PDFJAMA Neurol
January 2025
Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.
Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.
Design, Setting, And Participants: This phase 2 randomized double-blind placebo-controlled crossover clinical trial was conducted from October 21, 2020, to February 27, 2023, at 19 sites in the US.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!